Piper Sandler analyst David Amsellem lowered the firm’s price target on Organon to $22 from $32 to reflect certain realities associated with the business, while keeping an Overweight rating on the shares. The absence of exposure to generics, visibility into the stability of the established brands segment, and a growing women’s health footprint all justify an EBITDA multiple that is at a premium to the peer group, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OGN:
- Organon and Co call volume above normal and directionally bullish
- Organon, Samsung Bioepis announce FDA acceptace for review of Hadlima sBLA
- Organon price target lowered to $25 from $28 at Barclays
- Ex-Dividend Date Nearing for These 10 Stocks – Week of November 6-10, 2023
- Goldman downgrades Organon to Neutral on ‘agglomeration of issues’
